{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:07:32Z","timestamp":1792868852992,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pharming Healthcare, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03377-3","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:18:04Z","timestamp":1759911484000},"page":"6059-6077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Health Care Resource Utilization and Costs Among Patients with Activated Phosphoinositide\u00a03-Kinase Delta (PI3K\u03b4) Syndrome in the United States"],"prefix":"10.1007","volume":"42","author":[{"given":"Nicholas L.","family":"Rider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Mahendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"6160","key":"3377_CR1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, et al. Phosphoinositide\u00a03-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866\u201371.","journal-title":"Science"},{"key":"3377_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fimmu.2018.00369","volume":"9","author":"D Michalovich","year":"2018","unstructured":"Michalovich D, Nejentsev S. Activated PI3 kinase delta syndrome: from genetics to therapy. Front Immunol. 2018;9:369.","journal-title":"Front Immunol"},{"issue":"1","key":"3377_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13023-024-03215-9","volume":"19","author":"I Hitchcock","year":"2024","unstructured":"Hitchcock I, Skrobanski H, Matter E, et al. A qualitative study to explore the burden of disease in activated phosphoinositide\u00a03-kinase delta syndrome (APDS). Orphanet J Rare Dis. 2024;19(1):203.","journal-title":"Orphanet J Rare Dis"},{"key":"3377_CR4","doi-asserted-by":"publisher","first-page":"1208567","DOI":"10.3389\/fimmu.2023.1208567","volume":"14","author":"S Vanselow","year":"2023","unstructured":"Vanselow S, Wahn V, Schuetz C. Activated PI3K\u03b4 syndrome - reviewing challenges in diagnosis and treatment. Front Immunol. 2023;14:1208567.","journal-title":"Front Immunol"},{"issue":"1","key":"3377_CR5","doi-asserted-by":"publisher","first-page":"e20250003","DOI":"10.70962\/jhi.20250003","volume":"1","author":"MC Poli","year":"2025","unstructured":"Poli MC, Aksentijevich I, Bousfiha AA, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J Human Immunity. 2025;1(1):e20250003.","journal-title":"J Human Immunity"},{"issue":"1","key":"3377_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaip.2023.09.016","volume":"12","author":"AJ Cant","year":"2024","unstructured":"Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL. PI3K\u03b4 pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3K\u03b4 syndrome and beyond. J Allergy Clin Immunol Pract. 2024;12(1):69\u201378.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3377_CR7","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","volume":"9","author":"TI Coulter","year":"2018","unstructured":"Coulter TI, Cant AJ. The treatment of activated PI3K\u03b4 syndrome. Front Immunol. 2018;9:2043.","journal-title":"Front Immunol"},{"issue":"1","key":"3377_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s10875-024-01835-1","volume":"45","author":"F Barzaghi","year":"2024","unstructured":"Barzaghi F, Moratti M, Panza G, et al. Report of the Italian cohort with activated phosphoinositide\u00a03-kinase \u03b4 syndrome in the target therapy era. J Clin Immunol. 2024;45(1):58.","journal-title":"J Clin Immunol"},{"issue":"3","key":"3377_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","volume":"59","author":"M Jamee","year":"2020","unstructured":"Jamee M, Moniri S, Zaki-Dizaji M, et al. Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020;59(3):323\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"3377_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","volume":"139","author":"TI Coulter","year":"2017","unstructured":"Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide\u00a03-kinase \u03b4 syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597-606.e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3377_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","volume":"138","author":"E Elkaim","year":"2016","unstructured":"Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide\u00a03-kinase \u03b4 syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210-8.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"3377_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","volume":"9","author":"ME Maccari","year":"2018","unstructured":"Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide\u00a03-kinase \u03b4 syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide\u00a03-Kinase \u03b4 Syndrome Registry. Front Immunol. 2018;9:543.","journal-title":"Front Immunol"},{"issue":"1","key":"3377_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-025-03734-z","volume":"20","author":"M Mahendran","year":"2025","unstructured":"Mahendran M, Upton JEM, Ramasubramanian R, et al. Overall survival among patients with activated phosphoinositide\u00a03-kinase delta syndrome (APDS). Orphanet J Rare Dis. 2025;20(1):212.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3377_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s12325-024-03066-7","volume":"42","author":"K B\u00fcsch","year":"2025","unstructured":"B\u00fcsch K, Memmott HL, McLaughlin HM, Upton JEM, Harrington A. Genetic etiologies and outcomes in malignancy and mortality in activated phosphoinositide\u00a03-kinase delta syndrome: a systematic review. Adv Ther. 2025;42(2):752\u201371.","journal-title":"Adv Ther"},{"key":"3377_CR15","doi-asserted-by":"publisher","first-page":"1279652","DOI":"10.3389\/fimmu.2023.1279652","volume":"14","author":"S Vanselow","year":"2023","unstructured":"Vanselow S, Hanitsch L, Hauck F, et al. Future directions in the diagnosis and treatment of APDS and IEI: a survey of German IEI centers. Front Immunol. 2023;14:1279652.","journal-title":"Front Immunol"},{"issue":"1","key":"3377_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","volume":"149","author":"D Dimitrova","year":"2022","unstructured":"Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022;149(1):410-21.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3377_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","volume":"139","author":"Z Nademi","year":"2017","unstructured":"Nademi Z, Slatter MA, Dvorak CC, et al. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. J Allergy Clin Immunol. 2017;139(3):1046\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3377_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","volume":"143","author":"T Okano","year":"2019","unstructured":"Okano T, Imai K, Tsujita Y, et al. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase \u03b4 syndrome type\u00a01. J Allergy Clin Immunol. 2019;143(1):266\u201375.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"3377_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A, et al. A randomized, placebo-controlled phase\u00a03 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood. 2023;141(9):971\u201383.","journal-title":"Blood"},{"issue":"21","key":"3377_CR20","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","volume":"130","author":"VK Rao","year":"2017","unstructured":"Rao VK, Webster S, Dalm V, et al. Effective \u201cactivated PI3K\u03b4 syndrome\u201d-targeted therapy with the PI3K\u03b4 inhibitor leniolisib. Blood. 2017;130(21):2307\u201316.","journal-title":"Blood"},{"issue":"1","key":"3377_CR21","doi-asserted-by":"publisher","first-page":"ltae009","DOI":"10.1093\/immadv\/ltae009","volume":"4","author":"H IJspeert","year":"2024","unstructured":"IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ. Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives. Immunother Adv. 2024;4(1):ltae009.","journal-title":"Immunother Adv"},{"key":"3377_CR22","volume-title":"Biostatistical methods: the assessment of relative risks","author":"JM Lachin","year":"2009","unstructured":"Lachin JM. Biostatistical methods: the assessment of relative risks. Hoboken: Wiley; 2009."},{"issue":"1","key":"3377_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/sim.4780050106","volume":"5","author":"JM Taylor","year":"1986","unstructured":"Taylor JM. Choosing the number of controls in a matched case-control study, some sample size, power and efficiency considerations. Stat Med. 1986;5(1):29\u201336.","journal-title":"Stat Med"},{"issue":"381","key":"3377_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01621459.1983.10477915","volume":"78","author":"NE Breslow","year":"1983","unstructured":"Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc. 1983;78(381):1\u201312.","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"3377_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/pds.1673","volume":"17","author":"PC Austin","year":"2008","unstructured":"Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202\u201317.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3377_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev.publhealth.28.082206.094100","volume":"28","author":"AA Afifi","year":"2007","unstructured":"Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health. 2007;28:95\u2013111.","journal-title":"Annu Rev Public Health"},{"key":"3377_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103335","author":"G Tessarin","year":"2020","unstructured":"Tessarin G, Rossi S, Baronio M, et al. Activated phosphoinositide\u00a03-kinase delta syndrome 1: clinical and immunological data from an Italian cohort of patients. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9103335.","journal-title":"J Clin Med"},{"issue":"4","key":"3377_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/25785826.2023.2210366","volume":"46","author":"K Moriya","year":"2023","unstructured":"Moriya K, Mitsui-Sekinaka K, Sekinaka Y, et al. Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan. Immunol Med. 2023;46(4):153\u20137.","journal-title":"Immunol Med"},{"issue":"1","key":"3377_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gendis.2019.09.015","volume":"7","author":"A Singh","year":"2020","unstructured":"Singh A, Joshi V, Jindal AK, Mathew B, Rawat A. An updated review on activated PI3 kinase delta syndrome (APDS). Genes Dis. 2020;7(1):67\u201374.","journal-title":"Genes Dis"},{"issue":"1","key":"3377_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10875-023-01626-0","volume":"44","author":"LJ Berglund","year":"2024","unstructured":"Berglund LJ. Modulating the PI3K signalling pathway in activated PI3K delta syndrome: a clinical perspective. J Clin Immunol. 2024;44(1):34.","journal-title":"J Clin Immunol"},{"issue":"1","key":"3377_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaci.2018.08.039","volume":"143","author":"LD Notarangelo","year":"2019","unstructured":"Notarangelo LD. Hematopoietic stem cell transplantation for activated phosphoinositide\u00a03-kinase \u03b4 syndrome: who, when, and how? J Allergy Clin Immunol. 2019;143(1):91\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3377_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","volume":"36","author":"J Routes","year":"2016","unstructured":"Routes J, Costa-Carvalho BT, Grimbacher B, et al. Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12\u00a0months of immunoglobulin\u00a0G treatment. J Clin Immunol. 2016;36(5):450\u201361.","journal-title":"J Clin Immunol"},{"issue":"1","key":"3377_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","volume":"17","author":"G Yang","year":"2022","unstructured":"Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3377_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41409-019-0688-9","volume":"55","author":"A Ricci","year":"2020","unstructured":"Ricci A, Jin Z, Broglie L, et al. Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55(2):384\u201392.","journal-title":"Bone Marrow Transplant"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03377-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03377-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03377-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:18Z","timestamp":1763132658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03377-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3377"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03377-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amanda Harrington is an employee of Pharming Healthcare, Inc. Fran\u00e7ois Lalibert\u00e9, Guillaume Germain, and Malena Mahendran are employees of Groupe d\u2019analyse, which received research funding from Pharming Healthcare, Inc., to conduct this study. At the time of the study, Ana Urosevic was an employee of Groupe d\u2019analyse, SRI, Montr\u00e9al, Qu\u00e9bec, Canada. She is currently affiliated with Royal Bank of Canada, Toronto, Canada. Nicholas L. Rider received research funding from Pharming Healthcare, Inc., to conduct this study and serves on an advisory board and steering committee for Pharming Healthcare, Inc. No author received payment for the writing of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Analyses in this study included only deidentified insurance claims data; therefore, institutional review board approval and patient consent for study participation or publication of study findings were not required. Permission was obtained from Symphony Health Solutions Corporation, allowing use of data from its database for this study. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments and in compliance with the US patient confidentiality requirement of the Health Insurance Portability and Accountability Act.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}